The European LABDEL project and its relevance to the prevention and treatment of allergies

被引：14

作者：

Daniel, C.

Repa, A.

Mercenier, A.

Wiedermann, U.

Wells, J.

机构：

[1] Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Dept Specif Prophylaxis & Trop Med, A-1090 Vienna, Austria

[2] Inst Pasteur, Lab Bacteries Lact & Immunite Muqueuses, F-59019 Lille, France

[3] Med Univ Vienna, Dept Pediat, Div Neonatol & Intens Care, Vienna, Austria

[4] Univ Wageningen, Dept Anim Sci, Host Microbe Interact Grp, Wageningen, Netherlands

来源：

ALLERGY | 2007年 / 62卷 / 11期

关键词：

allergy; mice; mucosal delivery; primary/secondary prevention; probiotics; recombinant;

D O I：

10.1111/j.1398-9995.2007.01496.x

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

In March 2001, the European Commission funded a 3-year project (contract no. QLK3-CT-2000-00340) under the fifth Framework Programme to develop and test prototype products based on the oral delivery of vaccine and therapeutic agents using harmless lactic acid bacteria (LAB). The project, best known under its acronym LABDEL (for LAB delivery) also included research on LAB fermentation and technological innovations aimed at enhancing the efficiency of LAB delivery systems (1). One of the key scientific objectives was to investigate the possibility to prevent or treat a type I allergic disease using mucosal administration of LAB expressing the pollen allergen Bet v 1. The aim of this paper was to describe the background of the project with reference to a limited selection of articles and recent reviews as well as the results and major conclusions arising from this part of the project.

引用

页码：1237 / 1242

页数：6

共 28 条

[1] Oral administration of recombinant Lactococcus lactis expressing bovine β-lactoglobulin partially prevents mice from sensitization
Adel-Patient, K
Ah-Leung, S
Creminon, C
Nouaille, S
Chatel, JM
Langella, P
Wal, JM
[J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2005, 35 (04) : 539 - 546
[2] Role of regulatory T cells in allergy and asthma
Akbari, O
Stock, P
DeKruyff, RH
Umetsu, DT
[J]. CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (06) : 627 - 633
[3] Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria
Charng, Yuh-Chyang
Lin, Ching-Chi
Hsu, Ching-Hsaing
[J]. VACCINE, 2006, 24 (33-34) : 5931 - 5936
[4] Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice
Chatel, JM
Nouaille, S
Adel-Patient, K
Le Loir, Y
Boe, H
Gruss, A
Wal, JM
Langella, P
[J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2003, 69 (11) : 6620 - 6627
[5] Novel vaccines and adjuvants for allergen-specific immunotherapy
Crameri, Reto
Rhyner, Claudio
[J]. CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (06) : 761 - 768
[6] Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1
Daniel, C.
Repa, A.
Wild, C.
Pollak, A.
Pot, B.
Breiteneder, H.
Wiedermann, U.
Mercenier, A.
[J]. ALLERGY, 2006, 61 (07) : 812 - 819
[7] LACTOBACILLUS-PLANTARUM LDHL GENE - OVEREXPRESSION AND DELETION
FERAIN, T
GARMYN, D
BERNARD, N
HOLS, P
DELCOUR, J
[J]. JOURNAL OF BACTERIOLOGY, 1994, 176 (03) : 596 - 601
[8] FERREIRA FD, 1993, J BIOL CHEM, V268, P19574
[9] Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria:: impact of strain viability and in vivo persistence
Grangette, C
Müller-Alouf, H
Geoffroy, MC
Goudercourt, D
Turneer, M
Mercenier, A
[J]. VACCINE, 2002, 20 (27-28) : 3304 - 3309
[10] Potential and opportunities for use of recombinant lactic acid bacteria in human health
Hanniffy, S
Wiedermann, U
Repa, A
Mercenier, A
Daniel, C
Fioramonti, J
Tlaskolova, H
Kozakova, H
Israelsen, H
Madsen, S
Vrang, A
Hols, P
Delcour, J
Bron, P
Kleerebezem, M
Wells, J
[J]. ADVANCES IN APPLIED MICROBIOLOGY, VOL 56, 2004, 56 : 1 - 64

← 1 2 3 →